Is Boston Scientific Corporation overvalued?

In our latest published analysis dated 2026-05-12, BSX looks meaningfully undervalued. The price recorded at analysis is USD 54.1 versus a composite fair-value midpoint of USD 70.4 (range USD 55.9–USD 85.1), implying roughly 30.1% upside to the midpoint at that date.

What is BSX's fair value?

Our latest published report, analyzed 2026-05-12, gives BSX a composite fair-value range of USD 55.9–USD 85.1, with a midpoint of USD 70.4. The range is triangulated across multiple valuation models and weighted by reliability for Boston Scientific Corporation's archetype; it is a dated research output, not a live price.

Should I buy BSX now?

Our latest published rating for BSX, analyzed 2026-05-12, is Strong Buy with a confidence score of 88/100. Boston Scientific Corporation looks meaningfully undervalued at the analysis-date price of USD 54.1 versus a fair-value midpoint of USD 70.4. This is research for educational purposes, not personalized investment advice.

What are the biggest risks for BSX?

The top risks our latest published report dated 2026-05-12 flags for Boston Scientific Corporation are: Multiple Compression to Peer Median; Reimbursement Rate Cuts; WATCHMAN Normalization Stall.

What is BSX's rating?

Our latest published rating for BSX, analyzed 2026-05-12, is Strong Buy, with a confidence score of 88/100 and a moat score of 9/10. It reflects the composite fair-value range (USD 55.9–USD 85.1) versus the price recorded at analysis (USD 54.1).

What archetype is BSX?

In the latest published report analyzed 2026-05-12, Boston Scientific Corporation is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for BSX.

What is BSX's implied growth rate?

Reverse DCF for Boston Scientific Corporation (BSX) backs out the revenue or earnings growth rate the current share price implies, holding terminal value, margin, and discount-rate assumptions constant.

Is BSX's implied growth realistic?

We compare the implied rate to our own forecast deceleration curve and to the historical five-year actual. When the implied rate exceeds the realistic ceiling, the price is pricing in optimism the business has not yet demonstrated.

What discount rate is used for BSX?

Reverse DCF uses cost of equity (Ke), not WACC, to stay consistent with the EPS-based forward valuation models. Ke is derived from CAPM with adjusted beta; the strict and moderate variants are documented in the assumption ledger.

How does reverse DCF inform a buy or sell call?

When the implied growth rate is below our forecast, the market is underpricing the business; when it is above, the market is overpricing. The reverse-DCF read is one of four lenses that feed the composite fair-value range and the rating band.

BSX reverse DCF: implied growth at the report price

Latest published researchAnalyzed 2026-05-12; report age: stale; sources: unverified. Age and source freshness are disclosed but do not remove the latest published report from discovery or indexing. Prices and valuation figures are the analysis-date snapshot, not a live quote.

Direct answer

Boston Scientific is a mature compounder in the medical device sector, benefiting from a diverse portfolio across cardiovascular, MedSurg, and rhythm management, generating strong operating cash flows and consistent margin expansion. Fair value range: low $55.9, high $85.0, with mid-point at $70.4.

REVERSE DCF FAQ

BSX reverse dcf questions

Reverse DCF for Boston Scientific Corporation (BSX) backs out the revenue or earnings growth rate the current share price implies, holding terminal value, margin, and discount-rate assumptions constant.

FAQ

BSX — frequently asked questions

In our latest published analysis dated 2026-05-12, BSX looks meaningfully undervalued. The price recorded at analysis is USD 54.1 versus a composite fair-value midpoint of USD 70.4 (range USD 55.9–USD 85.1), implying roughly 30.1% upside to the midpoint at that date.

Metric	Current	Trigger threshold
Revenue growth decelerates below 6% falsification trigger.	Monitor	Deterioration versus the report thesis
Operating margins fail to sustain the 20.0% normalized assumption.	Monitor	Deterioration versus the report thesis
Peer forward P/E multiples compress, dragging the premium valuation.	Monitor

Line item	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$11.89B	$12.68B+6.6%	$14.24B+12.3%	$16.75B+17.6%	$20.07B+19.8%	+14.0%
Gross profit	$8.18B	$8.73B	$9.90B	$11.49B	$13.85B	+14.1%
Operating income	$1.82B	$2.03B	$2.42B	$3.00B	$3.97B	+21.5%
Net income	$1.04B	$698.0M-32.9%	$1.59B+127.8%	$1.85B+16.4%	$2.90B+56.8%	+29.2%
EPS (diluted)	$0.69	$0.45	$1.07	$1.25	$1.94	+29.5%
EBITDA	$2.51B	$2.75B	$3.45B	$3.86B	$5.10B	+19.4%
R&D	$1.20B	$1.32B	$1.41B	$1.62B	$2.05B	+14.3%
SG&A	$4.36B	$4.52B	$5.19B	$5.98B	$6.89B	+12.1%

BSX reverse dcf questions

BSX — frequently asked questions

BSX Boston Scientific Corporation fair value $56–$85

§1 Executive summary

Names readers of BSX also follow

§2 Bear case

Multiple Compression to Peer Median

Reimbursement Rate Cuts

WATCHMAN Normalization Stall

§3 Financial history

Income statement — last six periods

Quality scores

Numbers analysis

Read the full analysis — 11 more sections.